<DOC>
	<DOC>NCT00679055</DOC>
	<brief_summary>A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque macrophage content when compared to placebo (an approximate decrease of up to 30% is expected).</brief_summary>
	<brief_title>A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Participants with peripheral arterial disease Participants must be 18 to 85 years of age Females must be postmenopausal or sterile Participans with hepatic, HIV, endocrine, connective tissue, psychiatric disorders or uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>